the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
Published 4 months ago • 143 plays • Length 2:20Download video MP4
Download video MP3
Similar videos
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
3:28
biology of waldenström macroglobulinemia
-
3:48
impressive data: zanubrutinib for waldenström’s macroglobulinemia
-
2:26
an insight into the aims of the eurasian hematology-oncology group
-
3:16
aspen: zanubrutinib vs ibrutinib in waldenström's macroglobulinemia
-
46:10
atinary webinar series - ep 02 - ibm research
-
7:37
living with waldenstrom's with bob rupert
-
4:15
zanubrutinib versus rituximab-based chemoimmunotherapy in waldenström's macroglobulinemia
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl
-
2:56
insights into the healthtree foundation
-
1:43
current research in waldenström’s macroglobulinemia
-
5:54
updates from captivate: ibrutinib and venetoclax for cll
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
0:57
the potential of the tsafinder tool in hematological oncology
-
4:25
cll: state of the art in italy
-
1:54
fostamatinib and efgartigimod: novel agents in the treatment of itp
-
1:33
tumor-infiltrating lymphocyte therapy (til) video credit: iovance biotherapeutics
-
2:41
btk and plcg2 mutations in cll patients taking ibrutinib
-
2:07
phase i/ii study of edit-301, a novel gene-edited autologous hsc medicine, in patients with scd
-
1:52
safety and efficacy of idasanutlin in pv